A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS Trial

- Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H., Fentiman, I. S., George, W. D.

A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

- Dredge, Keith, Brennan, Todd V., Millward, Michael, Hammond, Edward, Lickliter, Jason D., Liwen, Lin, Bampton, Darryn, Handley, Paul, Lankesheer, Fleur, Morrish, Glynn, Yang, Yiping

A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing

- Glewis, Sarah, Alexander, Marliese, Khabib, Muhammad N. H., Brennan, Annabelle, Lazarakis, Smaro, Martin, Jennifer, Tie, Jeane, Lingaratnam, Senthil, Michael, Michael

Adjuvant chemotherapy in elderly patients with pancreatic cancer

- Nagrial, A. M., Chang, D. K., Pinese, M., Colvin, E. K., Scarlett, C. J., Chou, A., Kench, J. G., Sutherland, R. L., Horvath, L. G., Biankin, A. V., Nguyen, N. Q., Johns, A. L., Chantrill, L. A., Humphris, J. L., Chin, V. T., Samra, J. S., Gill, A. J., Pajic, M.

Adjuvant ovarian function suppression and cognitive function in women with breast cancer

- Phillips, Kelly-Anne, Regan, Meredith, Abdi, Ehtesham, Domchek, Susan, Feng, Yang, Price, Karen, Coates, Alan, Gelber, Richard, Maruff, Paul, Boyle, Frances, Forbes, John F., Ahles, Tim, Ribi, Karin, Fleming, Gini, Bernhard, Jürg, Francis, Prudence A., Puglisi, Fabio, Bellet, Meritxell, Spazzapan, Simon, Karlsson, Per, Budman, Daniel, Zaman, Khalil

Association of PHB 1630 C > T and MTHFR 677 C > T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study

- Jakubowska, A., Rozkrut, D., Antoniou, A., Hamann, U., Scott, R. J., McGuffog, L., Healy, S., Sinilnikova, O. M., Rennert, G., Lejbkowicz, F., Flugelman, A., Andrulis, I. L., Glendon, G., Ozcelik, H., Thomassen, M., Paligo, M., Aretini, P., Kantala, J., Aroer, B., Von Wachenfeldt, A., van der Luijt, B., Devilee, P., EMBRACE,, Easton, D. F., Peock, S., Frost, D., Platte, R., Ellis, S. D., Fineberg, E., Evans, D. G., Lalloo, F., Eeles, R., Jacobs, C., Adlard, J., Davidson, R., Eccles, D., Cole, T., Cook, J., Godwin, A., Bove, B., GEMO Study Collaborators,, Stoppa-Lyonnet, D., Caux-Moncoutier, V., Coupier, I., Peyrat, J.-P., Vennin, P., Muller, D., Fricker, J. P., Venat-Bouvet, L., Johannsson, O. Th., Isaacs, C., Schmutzler, R., Wappenschmidt, B., Meindl, A., Arnold, N., Varon-Mateeva, R., Niederacher, D., Sutter, C., Deissler, H., Preisler-Adams, S., Simard, J., Soucy, P., Durocher, F., Chenevix-Trench, G., Beesley, J., Chen, X., ConFab, K., Rebbeck, T., Couch, F., Wang, X., Lindor, N., Fredericksen, Z., Pankratz, V. S., Peterlongo, P., Bonanni, B., Fortuzzi, S., Peissel, B., Szabo, C., Mai, P. L., Loud, J. T., Lubinski, J., Liljegren, A., Loman, N., Herbst, K., Kristoffersson, U., Rosenquist, R., Karlsson, P., Stenmark-Askmalm, M., Melin, B., Nathanson, K. L., Domchek, S. M., Byrski, T., Huzarski, T., Gronwald, J., Menkiszak, J., Cybulski, C., Serrano, P., Osorio, A., Cajal, T. R., Tsitlaidou, M., Benitez, J., Gilbert, M., Rookus, M., Aalfs, C. M., Kluijt, I., Boessenkool-Pape, J. L., Meijers-Heijboer, H. E. J., Oosterwijk, J. C., Van Asperen, C. J., Blok, M. J., Nelen, M. R., Van Den Ouweland, A. M. W., Seynaeve, C.

COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer

- Tomlinson, I. P. M., Dunlop, M., Aaltonen, L. A., Hemminki, K., Lindblom, A., Forsti, A., Sieber, O., Lipton, L., van Wezel , T., Morreau, H., Wijnen, J. T., Devilee, P., Campbell, H., Scott, R., Zanke, B., Gallinger, S., Hudson, T., Koessler, T., Pharoah, P. D., Niittymakix, I., Tuupanenx, S.

CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

- Johnson, Nichola, Maguire, Sarah, Dennis, Joe, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baynes, Caroline, Freeman, Laura E. Beane, Morra, Anna, Beckmann, MW, Benitez, J, Bermisheva, M, Blomqvist, C, Boeckx, B, Bogdanova, NV, Bojesen, SE, Brauch, H, Brenner, H, Burwinkel, B, Kapoor, Pooja Middha, Campa, D, Canzian, F, Castelao, JE, Chanock, SJ, Chenevix-Trench, G, Clarke, CL, Børresen-Dale, AL, Alnæs, GIG, Sahlberg, KK, Ottestad, L, Tomczyk, Katarzyna, Kåresen, R, Schlichting, E, Holmen, MM, Sauer, T, Haakensen, V, Engebråten, O, Naume, B, Fosså, A, Kiserud, CE, Reinertsen, KV, Jones, Michael E., Helland, Å, Riis, M, Geisler, J, Conroy, DM, Couch, FJ, Cox, A, Cross, SS, Czene, K, Dörk, T, Eliassen, AH, Schoemaker, Minouk J., Engel, C, Evans, DG, Fasching, PA, Figueroa, J, Floris, G, Flyger, H, Gago-Dominguez, M, Gapstur, SM, García-Closas, M, Gaudet, MM, Gilham, Clare, Giles, GG, Goldberg, MS, González-Neira, A, Bowtell, DDL, deFazio, A, Webb, PM, Guénel, P, Hahnen, E, Haiman, CA, Håkansson, N, Bolla, Manjeet K., Hall, P, Hamann, U, Harrington, PA, Hart, SN, Hooning, MJ, Hopper, JL, Howell, A, Hunter, DJ, Clarke, C, Marsh, D, Wang, Qin, Scott, Rodney, Baxter, R, Yip, D, Carpenter, J, Davis, A, Pathmanathan, N, Simpson, P, Graham, D, Sachchithananthan, M, Amor, D

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

- Le Teuff, Gwénaël, Cozic, Nathalie, Largiadèr, Carlo R., Marinaki, Anthony, Jennings, Barbara A., Wettergren, Yvonne, Di Paolo, Antonello, Gross, Eva, Budai, Barna, Ackland, Stephen P., van Kuilenburg, André B. P., Mcleod, Howard L., Boyer, Jean-Christophe, Milano, Gérard, Thomas, F, Loriot, M-A, Kerr, D, Schellens, JHM, Laurent-Puig, P, Shi, Q, Pignon, J-P, Etienne-Grimaldi, M-C, Boige, Valérie, Diasio, Robert b., Taieb, Julien, Meulendijks, Didier, Palles, Claire, Schwab, Matthias, Deenen, Maarten

Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study

- Nair-Shalliker, Visalini, Bang, Albert, Smith, David P., Egger, Sam, Yu, Xue Qin, Chiam, Karen, Steinberg, Julia, Patel, Manish I., Banks, Emily, O'Connell, Dianne L., Armstrong, Bruce K.

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

- Wagner, U., Marth, C., Gebski, V., Lauraine, E. P., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R.

Genome-wide association study of germline variants and breast cancer-specific mortality

- Escala-Garcia, Maria, Figueroa, J, Flesch-Janys, D, Flyger, H, Gabrielson, M, Gago-Dominguez, M, Galle, E, Gapstur, SM, García-Closas, M, García-Sáenz, JA, Gaudet, MM, George, A, Georgoulias, V, Giles, GG, Glendon, G, Goldgar, DE, González-Neira, A, Alnæs, GIG, Grip, M, Guénel, P, Haeberle, L, Hahnen, E, Haiman, CA, Håkansson, N, Hall, P, Hamann, U, Hankinson, S, Harkness, EF, Harrington, PA, Hart, SN, Hartikainen, JM, Hein, A, Hillemanns, P, Hiller, L, Holleczek, B, Hollestelle, A, Guo, Qi, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie, Dörk, Thilo, Scott, Rodney J., Boeckx, B, Bojesen, SE, Bonanni, B, Børresen-Dale, AL, Brauch, H, Brenner, H, Brentnall, A, Brinton, L, Broberg, P, Canisius, Sander, Brock, IW, Brucker, SY, Burwinkel, B, Caldas, C, Caldés, T, Campa, D, Canzian, F, Carracedo, A, Carter, BD, Castelao, JE, Keeman, Renske, Chang-Claude, J, Chanock, SJ, Chenevix-Trench, G, Cheng, TYD, Chin, SF, Clarke, CL, Cordina-Duverger, E, Couch, FJ, Cox, DG, Cox, A, Dennis, Joe, Cross, SS, Czene, K, Daly, MB, Devilee, P, Dunn, JA, Dunning, AM, Durcan, L, Dwek, M, Earl, HM, Ekici, AB, Beesley, Jonathan, Eliassen, AH, Ellberg, C, Engel, C, Eriksson, M, Scott , RJ, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin

Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial

- Juraskova, I., Butow, P., Bonner, C., Bell, M. L., Smith, A. B., Seccombe, M., Boyle, F., Reaby, L., Cuzick, J., Forbes, J. F.

In utero exposure to breast cancer treatment: a population-based perinatal outcome study

- Safi, Nadom, Anazodo, Antoinette, Dickinson, Jan E., Lui, Kei, Wang, Alex Y., Li, Zhuoyang, Sullivan, Elizabeth A.

Integrin αvβ6-associated ERK2 mediates MMP-9 secretion in colon cancer cells

- Gu, X., Niu, J., Dorahy, D. J., Scott, R. D., Agrez, M. V.

Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area

- Isenring, E. A., Capra, S., Bauer, J. D.

O⁶-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

- Watson, A. J., Middleton, M. R., Haydon, A., Kefford, R., Lorigan, P., Mortimer, P., Sabharwal, A., Hayward, O., Margison, G. P., McGown, G., Thorncroft, M., Ranson, M., Hersey, P., McArthur, G., Davis, I. D., Thomson, D., Beith, J.

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial

- Blinman, Prunella, Mileshkin, Linda, O'Connell, Rachel, Creutzberg, Carien L., Stockler, Martin R., Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

- Khoja, Leila, Kibiro, Minnie, Metser, Ur, Gedye, Craig, Hogg, David, Butler, Marcus O, Atenafu, Eshetu G, Joshua, Anthony M

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

- Bernhard, J., Zahrieh, D., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Coates, A. S., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., Forbes, J. F., Aebi, S., Yeo, W., Thurlimann, B.